XSHG
600833
Market cap346mUSD
Oct 09, Last price
10.56CNY
1D
1.64%
1Q
9.77%
Jan 2017
-48.61%
Name
Shanghai No.1 Pharmacy Co Ltd
Chart & performance
P/E
40.79
P/S
1.11
EPS
0.26
Div yield, %
2.12%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
6.07%
Revenues
2.13b
+11.23%
Net income
58m
-64.59%
CFO
89m
+81.29%
Dividend
Jun 26, 20260.078 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai No.1 Pharmacy Co., Ltd., headquartered in Shanghai, China, is primarily involved in the distribution and retail of a diverse array of pharmaceutical and health-related products. Their comprehensive selection features both traditional Chinese and modern Western medicines, nutritional supplements, medical equipment, and various herbal remedies. Additionally, the company extends its services to offer expert guidance on responsible and safe medication practices, with a specific focus on managing chronic health conditions.
Key people
Chairman of the Board · since 2017
Jie Zhou
General Manager · since 2018
Shunliang Wang
Deputy General Manager · since 2011
Yanna Yan
Deputy General Manager · since 2019
Zhiyi Chen
Director · since 2011
Yiyu Weng
Director · since 2011
Zhijie Xiao
Director · since 2008
Zhi Zhang
Director · since 2011
Xiuyu Mi
Independent Director · since 2011
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||